Close Menu

NEW YORK — Having launched a digital screening test for preterm birth in November, diagnostics firm Nixxi is preparing this quarter to release a mass spectrometry-based test for predicting preterm birth and infant morbidity.

The company is currently working out a partnership with a CLIA lab and completing a validation study that to support the launch of the test, said Avi Patil, founder and CEO of the Phoeniz, Arizona-based firm.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.